1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

Stada Launches Lecigon In Germany And Austria

Value-Added Parkinson's Disease Treatment Rolled Out In Continental Europe

 
• By Dave Wallace

Stada is kicking off the launch of its Lecigon gel in continental Europe by rolling out the value-added product – which combines levodopa, carbidopa and entacapone infused via a lightweight pump – in Germany and Austria.

Germany Austria flags
The product is initially being rolled out in Germany and Austria • Source: Shutterstock

Stada has begun the roll-out of its Lecigon (levodopa/carbidopa/entacapone) infusion pump product in continental Europe, starting in Germany and Austria. The value-added treatment for Parkinson’s disease – which was gained through Stada’s acquisition of Sweden’s Lobsor Pharmaceuticals last year – had already been launched in Sweden, Denmark, Norway and Finland ahead of the deal. (Also see "Stada Strikes Deals With Lobsor And MediPharm" - Generics Bulletin, 8 October, 2020.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine

 
• By Adam Zamecnik

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.

Cipla Becomes Formosa’s Latest Clobetasol Partner With 11-Country Deal

 
• By Dean Rudge

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.

Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales

 
• By Dean Rudge

Amneal has spoken excitedly about its Crexont (carbidopa/levodopa) extended-release capsules as the Parkinson’s disease drug passes six months on the market.

Hyloris Celebrates Valacyclovir FDA Filing Amid Series Of Announcements

 
• By Adam Zamecnik

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

More from Products

Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab

 
• By Dave Wallace

Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.